New Centers for Disease Control and Prevention data is showing that newly released RSV vaccines are highly effective at keeping infants from becoming hospitalized.
The real-world usage of nirsevimab so far has outperformed data from clinical trials. Prior to its release, officials said nirsevimab reduced the risk of hospitalizations related to RSV among infants by 70%-75%. The study looked at 699 infants from October 2023 through February 2024. CDC officials did caution that its overall effectiveness may be lower once a full RSV season is complete. Generally, RSV activity declines in late March.SEE MORE: CDC: 128 pregnant people and 25 infants received the wrong RSV shot
Entertainment Entertainment Latest News, Entertainment Entertainment Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Collider - 🏆 1. / 98 Read more »